TRIPLE NEGATIVE BREAST NEOPLASMS
Clinical trials for TRIPLE NEGATIVE BREAST NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new TRIPLE NEGATIVE BREAST NEOPLASMS trials appear
Sign up with your email to follow new studies for TRIPLE NEGATIVE BREAST NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame aggressive breast cancer
Disease control OngoingThis study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug combo in final testing
Disease control OngoingThis phase 3 trial tests whether adding capivasertib (a targeted drug) to standard chemotherapy (paclitaxel) helps people with advanced triple-negative breast cancer live longer. About 923 participants receive either the combination or a placebo plus chemotherapy. The study is no…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug BT8009 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could adding capecitabine boost chemo success in Triple-Negative breast cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug capecitabine to standard chemotherapy improves outcomes for people with early triple-negative breast cancer. The study involves 325 participants and aims to see if the combination leads to a higher rate of complete tumor disappeara…
Matched conditions: TRIPLE NEGATIVE BREAST NEOPLASMS
Phase: PHASE3 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:52 UTC